Ipamorelin 5mg

Important Note

This page is informational and does not authorize use. Peptify clients should complete assessment, disclose medications and health history, and follow the clinician-approved plan only.

Do not start, stop, combine, or change a protocol based only on website content.
Emergency symptoms require urgent medical care, not a website or routine follow-up message.

Quickstart Highlights

Ipamorelin is a synthetic pentapeptide that acts as a selective growth-hormone secretagogue — a ghrelin / GHS-R1a receptor agonist that prompts the pituitary to release short pulses of growth hormone[1][2]. Its distinguishing feature is selectivity for GH release with minimal effect on cortisol, ACTH or prolactin, separating it from the older GHRP-2 / GHRP-6 peptides[3]. It is an unapproved research chemical, not a medicine: its only controlled human trial (a Phase II study in postoperative ileus) failed its primary endpoint and development was discontinued, so the popular muscle, fat-loss, anti-aging, recovery and sleep claims are not proven in controlled human outcome trials — presented for research and educational use only.

Add 3.0 mL bacteriostatic water to one 5 mg vial → ~1.67 mg/mL (1,670 mcg/mL).
100–250 mcg once daily, titrated upward gradually across an 8–12 week course (often dosed before bed, fasted).
At ~1.67 mg/mL, 1 unit ≈ 16.7 mcg; 100 mcg ≈ 6 units and 250 mcg ≈ 15 units on a U-100 syringe.
Lyophilized: refrigerate at 2–8 °C (35.6–46.4 °F) or freeze at −20 °C (−4 °F); once reconstituted, refrigerate at 2–8 °C and do not freeze the solution.
Important: Start with the Prep & Injection Guide — it covers the preparation and safety basics every protocol on this site assumes.

Dosing & Reconstitution Guide

A single practical dilution with accurate once-daily dosing, step by step

Standard / Gradual Approach (3 mL = ~1.67 mg/mL)

Phase / Week(s)	Daily Dose & Frequency	Volume (U-100 units / mL)
Weeks 1–2	100 mcg (1× daily)	6 units (0.06 mL)
Weeks 3–4	150 mcg (1× daily)	9 units (0.09 mL)
Weeks 5–8	200 mcg (1× daily)	12 units (0.12 mL)
Weeks 9–12	250 mcg (1× daily)	15 units (0.15 mL)

Reconstitute: Add 3.0 mL bacteriostatic water to one 5 mg vial → final concentration ~1.67 mg/mL (1,670 mcg/mL).
Typical daily range: 100–250 mcg once daily, raised gradually over an 8–12 week course.
Easy measuring: At ~1.67 mg/mL, 1 unit ≈ 16.7 mcg on a U-100 syringe. Because these doses sit at roughly 6–15 units, a 30- or 50-unit insulin syringe makes the small marks easier to read.
Storage: Lyophilized: refrigerate at 2–8 °C or freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C and do not freeze the mixed solution.
Frequency: one subcutaneous injection each day, most often 30–60 minutes before bed on an empty stomach to align with the body’s natural nocturnal GH pulse[4][5]. Titrate up only as tolerated. These figures come from commonly cited reference protocols, not from approved human dosing.

Reconstitution Steps

Draw 3.0 mL of bacteriostatic water into a sterile syringe.

Release it slowly down the vial’s inner wall to limit foaming.
Swirl or roll gently until fully dissolved — don’t shake.
Label with the date and concentration, then refrigerate at 2–8 °C (35.6–46.4 °F), shielded from light.
Because Ipamorelin doses are small, every microgram counts — measure carefully on a fine-marked U-100 syringe. Avoid freezing the reconstituted solution, since freeze–thaw can denature the peptide.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Supplies Needed

Quantities below assume an 8–16 week course of once-daily injections with gradual titration.

A 5 mg vial covers several weeks at 100–250 mcg/day, so a full course needs only a few vials.
8 weeks: ~2 vials
12 weeks: ~2–3 vials
16 weeks: ~3 vials
Per injection: 1 syringe
8 weeks (once daily): ~56 syringes
16 weeks (once daily): ~112 syringes
Use ~3.0 mL per 5 mg vial for reconstitution.
8 weeks (2 vials): ~6 mL → 1 bottle
16 weeks (3 vials): ~9 mL → 1 bottle
One for the vial stopper + one for the injection site each day.
Per injection: 2 swabs
8 weeks (once daily): ~112 swabs → 1–2 boxes

Protocol Overview

A concise summary of the once-daily regimen, drawn from commonly cited reference protocols.

▪Goal: Trigger short, pulsatile releases of the body’s own growth hormone via the GHS-R1a receptor[1][2] — downstream effects on muscle, fat or recovery are not established in controlled human trials.
▪Schedule: Daily subcutaneous injections for 8–12 weeks (optionally extended to ~16 weeks), often followed by a short off-cycle.
▪Dose Range: 100–250 mcg per day with gradual titration; ~200 mcg is a common middle dose.
▪Reconstitution: 3.0 mL bacteriostatic water per 5 mg vial gives ~1.67 mg/mL for accurate unit measurements.
▪Storage: Keep the dry vial cold at 2–8 °C (or frozen at −20 °C); once mixed, refrigerate at 2–8 °C and do not freeze the solution.

Dosing Protocol

A suggested daily titration approach based on common reference doses.

▪Start: Begin at 100 mcg once daily to gauge tolerability.
▪Titrate: Increase by roughly 50 mcg every one to two weeks as tolerated.
▪Target: Reach about 200–250 mcg daily by weeks 5–12.
▪Cycle Length: Typically 8–12 weeks; some references extend to ~16 weeks, followed by a 2–4 week pause.
▪Timing: Inject at a consistent time each day — usually before bed, fasted — and rotate injection sites systematically.

Storage Instructions

Correct storage is what preserves the peptide’s stability and activity.

▪Lyophilized: Hold the dry vial at 2–8 °C for short-term use or −20 °C (−4 °F) for longer storage, in dry, dark conditions[6].
▪Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F) and use within about 4 weeks; do not freeze the mixed solution, as freezing can denature peptides[7].
▪Handling: Let cold or frozen vials warm to room temperature before opening so condensation won’t form, and keep the solution clear of heat and direct light.
▪Freeze–thaw: Avoid repeated freeze–thaw cycles of the reconstituted solution.

Important Notes

Practical points that keep daily administration safe and consistent.

▪Sterile technique: Use a fresh sterile U-100 insulin syringe each time and drop it straight into a puncture-proof sharps container afterward[8].
▪Site rotation: Move between abdomen, thighs and upper arms to reduce local irritation and lipohypertrophy[9].
▪Short half-life: Ipamorelin has a brief ~2 hour half-life, producing a single short GH pulse[4], so consistent daily timing matters.
▪Recordkeeping: Log the daily dose, injection site and any observations to keep the protocol consistent.
▪Regulatory note: Ipamorelin is not FDA-approved and is prohibited in sport under WADA category S2 (peptide hormones / GH secretagogues)[10].

How This Works

Ipamorelin is a synthetic pentapeptide and a selective growth-hormone secretagogue. It binds the ghrelin / growth-hormone secretagogue receptor (GHS-R1a) on the pituitary, mimicking the natural hormone ghrelin and triggering a short, pulsatile release of growth hormone[1][2].

Its defining trait is selectivity: at effective doses it does not meaningfully raise cortisol, ACTH or prolactin — the key distinction from the older GHRP-2 and GHRP-6 peptides[3]. After a subcutaneous dose, GH tends to peak within roughly 40 minutes and return toward baseline within about 2–3 hours, reflecting a brief ~2 hour half-life[4]. It is often paired with a GHRH analog such as CJC-1295 in research settings to combine the two complementary GH-release pathways.
Critical honesty: Ipamorelin is not FDA-approved. Its only controlled human trial — a Phase II study for postoperative ileus — failed its primary endpoint, and clinical development was discontinued[5]. The popular uses (muscle gain, fat loss, anti-aging, recovery, sleep) rest on the assumption that nudging GH upward produces those outcomes, but they are not demonstrated in controlled human outcome trials for Ipamorelin.
Ipamorelin is an unapproved research chemical presented here for research and educational purposes only — not a medicine and not for human consumption.

Lifestyle Factors

Habits that may support the body’s natural GH rhythm alongside any research protocol.

▪Nutrition: Keep protein intake adequate and inject on a relatively empty stomach — high blood sugar and insulin can blunt the GH response.
▪Activity & rest: Pair appropriate training with real recovery; avoid chronic overtraining.
▪Sleep: Aim for 7–9 hours, since the body’s largest natural GH pulse occurs during deep sleep.
▪Stress: Manage stress with evidence-based practices, as elevated cortisol can dampen GH output.

Potential Benefits & Side Effects

What the preclinical and limited human literature describe; controlled human efficacy evidence is lacking and individual results vary.

▪Selective GH release: Stimulates the body’s own GH pulses with minimal effect on cortisol, ACTH or prolactin[1][3].
▪Body-composition claims (unproven): Muscle, fat-loss and recovery benefits are popularly attributed to GH elevation but are not established for Ipamorelin in controlled human trials.
▪GI motility (preclinical/early): Ipamorelin showed pro-motility effects on the gut via GHS-R1a, the basis of its failed postoperative-ileus trial[5].
▪Note on humans: No completed trial has shown clinical benefit; the one controlled study failed its endpoint[5].
▪Injection-site reactions: Mild redness, tenderness or soreness can occur; rotating sites helps.
▪Transient effects: Occasional reports of head-rush, mild water retention or increased hunger (a ghrelin-receptor effect).
▪Unknown long-term profile: Human safety data is very limited, so caution and monitoring are advised.
▪Sport restriction: Ipamorelin is a WADA-prohibited substance (category S2) for athletes.

Injection Technique

General subcutaneous technique, following established clinical best-practice guidance[11][12].

▪Wash your hands well with soap and water.
▪Wipe the vial stopper with an alcohol swab and let it air-dry.
▪Choose a site (abdomen, thigh, or upper arm) and clean it with a fresh alcohol swab, letting it dry fully[12].
▪Draw the intended dose, then check for air bubbles and push any out.
▪Pinch a skinfold at the chosen site between thumb and forefinger.
▪Insert the needle into the pinch at a 45–90-degree angle (use 45 degrees if the fat layer is thin)[11].
▪Skip aspiration for subcutaneous shots — it isn’t needed[11].
▪Press the plunger slowly and steadily until it’s fully down.
▪Wait 5–10 seconds, then pull the needle straight out to prevent leakage.
▪Drop the used syringe straight into a puncture-proof sharps container — never recap a needle.
▪Return the reconstituted vial to the fridge right away.
▪Rotate the injection site each day to prevent irritation and lipohypertrophy[9].
▪Watch the site for excess redness, swelling, or signs of infection.

Recommended Source

For high-purity research peptides, we point researchers to Prime Lab Peptides for Ipamorelin (5 mg).

▪Top-rated on Trustpilot: Independently reviewed as the highest-rated peptide lab on Trustpilot — making it the best current source in the USA. Open source
▪Third-party tested: Every batch ships with a Certificate of Analysis (COA) confirming purity and composition.
▪Consistent quality: ISO-aligned manufacturing and handling keep product integrity reliable batch to batch.
▪Cold-chain integrity: Temperature-controlled shipping and storage across the whole fulfilment chain.
▪Research-grade purity: Fit for educational and research use that demands high-quality peptides.
Note: Product availability and specifications subject to change. Verify current product details on supplier website.
Shop at Prime Lab Peptides →

References

Reference-derived details for Ipamorelin 5mg.

Ipamorelin (5mg Vial) Dosage Protocol Open source
1 Bioorganic & Medicinal Chemistry Letters (PubMed) Raun et al. — Ipamorelin: the first selective growth-hormone secretagogue, characterizing GHS-R1a binding and GH release. View Source ↗ Open source
2 Growth Hormone Secretagogue Receptor (Ghrelin Receptor) Pharmacology of GHS-R1a: ghrelin-mimetic agonism and pulsatile GH stimulation. View Source ↗ Open source
3 European Journal of Endocrinology Selectivity of Ipamorelin: GH release without significant ACTH, cortisol or prolactin elevation. View Source ↗ Open source
4 Pharmacokinetics of Ipamorelin (PubMed) Onset and short ~2 hour half-life of Ipamorelin after subcutaneous administration. View Source ↗ Open source
5 ClinicalTrials.gov Phase II trial of Ipamorelin for postoperative ileus — primary endpoint not met; development discontinued. View Source ↗ Open source
6 Peptide Storage Guide Best practices for storing lyophilized peptides (temperature, humidity and light protection). View Source ↗ Open source
7 Bacteriostatic Water Guidance Bacteriostatic water for injection: multi-dose vial stability and handling. View Source ↗ Open source
8 NCBI Bookshelf Best practices for subcutaneous injection: aseptic technique and sharps disposal. View Source ↗ Open source
9 NCBI Bookshelf — Site Rotation Injection-site rotation to reduce local irritation and lipohypertrophy. View Source ↗ Open source
10 WADA Prohibited List Growth-hormone secretagogues, including Ipamorelin, classified under category S2 (prohibited in sport). View Source ↗ Open source
11 Centers for Disease Control and Prevention (CDC) Subcutaneous injection technique: angle, site and no-aspiration guidance. View Source ↗ Open source
12 Subcutaneous Injection Technique (Patient Education) How to administer a subcutaneous injection: clinical technique guidelines. View Source ↗ Open source
13 Prime Lab Peptides Ipamorelin (10 mg) product page — purity specifications and certificates of analysis. View Source ↗ Open source

Contents